drugset / Trial / NCT02572323

Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

NCT02572323

RandomizedCrossoverSingle-blindTreatment

Summary

The aim of this study is to test whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, will significantly improve memory and thinking in HIV.

Timeline

Start
2017-02-15
Primary completion
2023-10-15
Completion
2023-10-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tesamorelin Peptide 1.4 mg Other